EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug

NeuroSense Therapeutics Ltd. NRSN on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS).

These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement.

NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached.

In August, NeuroSense Therapeutics released 12-month iron biomarker data from its PARADIGM Phase 2b study for PrimeC in ALS patients.

The results demonstrated the target engagement of PrimeC in iron regulation, which is linked to disease mitigation and improved survival.

These changes in iron metabolism align with improved clinical outcomes. Patients on PrimeC maintained better functionality and survival rates than those on placebo.

In July, 12-month data of the PARADIGM Phase 2b study showed a significant improvement in the rate of decline of ALS Functional Rating Scale-Revised scores and survival rates for subjects who received PrimeC from the start of the trial compared to those who started on placebo.

Specifically, the intent to treat analysis at 12 months revealed a difference of 6.5 points in the ALSFRS-R, representing a 36% improvement and a statistically significant P value of 0.009.

In addition, at 12 months, participants on PrimeC demonstrated 43% better survival than those initially on placebo.

Additional results from the PARADIGM Phase 2b study showed a complication-free survival revealed a 57% difference in favor of PrimeC over placebo after 12 months of treatment in the Intent to Treat population and demonstrated an outcome of 73% (p=0.02) difference in favor of PrimeC over placebo after 12 months of treatment in the pre-defined Per Protocol Population.

Price Action: NRSN stock closed at $0.74 on Tuesday.

Read Next:

• Why Is Clinical Diagnostics Focused Trinity Biotech Stock Trading Higher On Tuesday?